NCT02727777 2020-03-12Phase II Study of TAK228 in Relapsed LymphomaM.D. Anderson Cancer CenterPhase 1/2 Terminated4 enrolled 9 charts
NCT03205891 2018-01-17Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell LymphomasM.D. Anderson Cancer CenterPhase 1 Withdrawn